I was glad to see more transparency in how the Officers will be compensated. It also makes me feel more comfortable to know that they have disclosed this ESOP set up during 2016 which awards them share options that are held by a trustee and vest after a period of two years. Why is this important to me? Because now it is transparent and clear that the top management will receive a lot of shares as described below and this is a serious driver and motivator for this management team to make serious strides forward and the better they do the higher the stock price will go and directly affect their payoff. It also motivates them to get the company and stock to a point where they can uplist. These kind of incentive programs are often used in companies to motivate the management team to perform and meet progress deadlines and goals.
The most important part to me is this:
(3) Under the Company’s 2016 ESOP, 10 million options were granted to Mr. Bignitz, 750,000 options were granted to Mr. De-Saban, and 7 million options were granted to Dr. Baruch and Mr. Sinai during 2016. Subject to the provisions of applicable Israeli laws, these options are held by a trustee and vest after a period of two years and, as a result, are not included in the above table.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS Back to Table of Contents
The table below provides information regarding the beneficial ownership of the common stock as of March 31, 2017, of (1) each person or entity who owns beneficially 5% or more of the shares of our outstanding common stock, (2) each of our directors, (3) each of the Named Executive Officers, (4) our directors and officers as a group and (5) certain employees of our subsidiary OWC. Except as otherwise indicated, and subject to applicable community property laws, we believe the persons named in the table have sole voting and investment power with respect to all shares of common stock held by them. Unless otherwise indicated below, the address for each beneficial owner listed is c/o OWC Pharmaceutical Research Corp., at 30 Shacham Street, P.O. Box 8324, Petach Tikva, 4918103, Israel.
Name of Beneficial Owner Shares of Common Stock Beneficially Owned (1) Percent of Class (2)
Mordechai Bignitz, Chief Executive Officer (3) 0 0 %
Shmuel De-Saban, Chief Financial Officer (3) 195,416 *
Dr. Yehuda Baruch, Chief Science Officer (3) 0 0%
All directors and executive officers as a group (3 persons) 195,416 *
Alon Sinai, COO and Interim CEO of OWC (3) 1,011,250 0.70 %
Yehuda Baruch, Director of Research and Regulatory Affairs for OWC (3) 2,120,000 1.46 %
* Less than one percent.
(1) Represents shares of common stock held as of March 31, 2017 plus shares of common stock that may be acquired upon exercise of options, warrants and other rights exercisable within 60 days of March 31, 2017.
(2) Based on 144,719,287 shares of our common stock outstanding as of March 31, 2017.
(3) Under the Company’s 2016 ESOP, 10 million options were granted to Mr. Bignitz, 750,000 options were granted to Mr. De-Saban, and 7 million options were granted to Dr. Baruch and Mr. Sinai during 2016. Subject to the provisions of applicable Israeli laws, these options are held by a trustee and vest after a period of two years and, as a result, are not included in the above table.
- 72 -
The most important part to me is this:
(3) Under the Company’s 2016 ESOP, 10 million options were granted to Mr. Bignitz, 750,000 options were granted to Mr. De-Saban, and 7 million options were granted to Dr. Baruch and Mr. Sinai during 2016. Subject to the provisions of applicable Israeli laws, these options are held by a trustee and vest after a period of two years and, as a result, are not included in the above table.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS Back to Table of Contents
The table below provides information regarding the beneficial ownership of the common stock as of March 31, 2017, of (1) each person or entity who owns beneficially 5% or more of the shares of our outstanding common stock, (2) each of our directors, (3) each of the Named Executive Officers, (4) our directors and officers as a group and (5) certain employees of our subsidiary OWC. Except as otherwise indicated, and subject to applicable community property laws, we believe the persons named in the table have sole voting and investment power with respect to all shares of common stock held by them. Unless otherwise indicated below, the address for each beneficial owner listed is c/o OWC Pharmaceutical Research Corp., at 30 Shacham Street, P.O. Box 8324, Petach Tikva, 4918103, Israel.
Name of Beneficial Owner Shares of Common Stock Beneficially Owned (1) Percent of Class (2)
Mordechai Bignitz, Chief Executive Officer (3) 0 0 %
Shmuel De-Saban, Chief Financial Officer (3) 195,416 *
Dr. Yehuda Baruch, Chief Science Officer (3) 0 0%
All directors and executive officers as a group (3 persons) 195,416 *
Alon Sinai, COO and Interim CEO of OWC (3) 1,011,250 0.70 %
Yehuda Baruch, Director of Research and Regulatory Affairs for OWC (3) 2,120,000 1.46 %
* Less than one percent.
(1) Represents shares of common stock held as of March 31, 2017 plus shares of common stock that may be acquired upon exercise of options, warrants and other rights exercisable within 60 days of March 31, 2017.
(2) Based on 144,719,287 shares of our common stock outstanding as of March 31, 2017.
(3) Under the Company’s 2016 ESOP, 10 million options were granted to Mr. Bignitz, 750,000 options were granted to Mr. De-Saban, and 7 million options were granted to Dr. Baruch and Mr. Sinai during 2016. Subject to the provisions of applicable Israeli laws, these options are held by a trustee and vest after a period of two years and, as a result, are not included in the above table.
- 72 -
4
